| Literature DB >> 30219681 |
Aline Maria Stolf1, Cibele Campos Cardoso1, Helen de Morais1, Carlos Eduardo Alves de Souza1, Luís Alexandre Lomba1, Anna Paula Brandt2, Jonathan Paulo Agnes1, Flávia Caroline Collere1, Claudia Martins Galindo1, Claudia Rita Corso1, Katherinne Maria Spercoski3, Rosangela Locatelli Dittrich4, Aleksander Roberto Zampronio1, Silvia Maria Suter Correia Cadena2, Alexandra Acco5.
Abstract
The present study evaluated the effects of acute treatment with silymarin, an extract that is obtained from Silybum marianum, on angiogenesis, oxidative stress, and inflammation in normoglycemic and diabetic mice. Diabetes was induced by streptozotocin (80 mg/kg, intraperitoneal) in male Swiss mice, 6 weeks of age. A polyether-polyurethane sponge was surgically implanted in the back of the mice as a model of healing in both diabetic and normoglycemic animals that were treated with oral silymarin or water for 10 days. The pancreas, liver, kidneys, blood, and sponges were collected and analyzed. Diabetes led to impairments of antioxidant defenses, reflected by a reduction of pancreatic superoxide dismutase and hepatic and renal catalase and an increase in pancreatic lipoperoxidation. An inflammatory process was observed in diabetic mice, reflected by an increase in pancreatic tumor necrosis factor α (TNF-α) and the infiltration of inflammatory cells in islets. The number of vessels was lower in the implanted sponges in diabetic mice. Silymarin treatment attenuated this damage, restoring antioxidant enzymes and reducing pancreatic TNF-α and inflammatory infiltration. However, silymarin treatment did not restore angiogenesis or glycemia. In conclusion, treatment with silymarin red uced oxidative stress and inflammation that were induced in the model of streptozotocin-induced diabetes in several organs, without apparent toxicity. Silymarin may be a promising drug for controlling diabetic complications.Entities:
Keywords: Angiogenesis; Diabetes; Inflammation; Oxidative stress; Silymarin; Streptozotocin
Mesh:
Substances:
Year: 2018 PMID: 30219681 DOI: 10.1016/j.biopha.2018.09.042
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529